However, a recent study found the anti-tumor efficacy of neoantigen/toll-like receptor 3 (TLR3)/CD40 agonist vaccine and neoantigen-specific CX3CR1+ CD8+ T cell generation relied on CD40 and CD80/86, rather than the CD70 signaling pathway 90. This evidence concerns the gene CD8A and neoplasm.